CV Sciences (CVSI) Free Cash Flow Growth (3y) (2014 - 2026)
CV Sciences (CVSI) Free Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 39.19% |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -53.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.50% |
| Dec 31, 2025 | -51.42% |
| Sep 30, 2025 | 16.63% |
| Jun 30, 2025 | 30.13% |
| Mar 31, 2025 | 31.65% |
| Dec 31, 2024 | 46.13% |
| Sep 30, 2024 | 57.31% |
| Jun 30, 2024 | 73.50% |
| Mar 31, 2024 | 33.02% |
| Dec 31, 2023 | 63.19% |
| Sep 30, 2023 | 76.48% |
| Jun 30, 2023 | 35.65% |
| Mar 31, 2023 | 36.65% |
| Dec 31, 2022 | 26.75% |
| Sep 30, 2022 | 18.99% |
| Jun 30, 2022 | -34.66% |
| Mar 31, 2022 | -35.69% |
| Dec 31, 2021 | -38.71% |
| Sep 30, 2021 | -32.84% |
| Jun 30, 2021 | -40.87% |